California News Reporter

Delveinsight Business Research LLP

As per DelveInsight, the Endometriosis therapeutics market is anticipated to evolve immensely in the coming years owing to the rise in the number of prevalent cases, the improvement in the research and development activities, and the launch of novel therapies. Some of the key companies in the Endometriosis therapeutics market include ObsEva, Myovant Sciences, Bayer, Merck, Mitsubishi Tanabe Pharma Development America, and others.

“Endometriosis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Endometriosis Market. 

The Endometriosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Endometriosis Pipeline Analysis

The report provides insights into: 

• The report provides detailed insights into the emerging therapies for the treatment of Endometriosis and the aggregate therapies developed by major pharma companies.

• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Endometriosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) 

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Route of Administration

Endometriosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Parenteral

• Intravenous 

• Subcutaneous

• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides 

• Polymer 

• Small molecule

• Gene therapy

Learn How the Ongoing Clinical & Commercial Activities will Affect the Endometriosis Therapeutic Segment @

https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight

Endometriosis Therapeutics Landscape

Several major pharma and biotech giants are developing therapies for Endometriosis. Currently, ObsEva is leading the therapeutic market with its Endometriosis drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Endometriosis Therapeutics Market Include:

AbbVie, AstraZeneca, Bayer, BCI Pharma, Camurus, Celmatix, Chugai Pharmaceutical, Dexa Medica Group, Enteris BioPharma, Ferring Pharmaceuticals, Forendo Pharma, Hope Medicine, Jiangsu HengRui Medicine Co., Ltd., Kissei Pharmaceuticals, Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Development America, Myovant Sciences, Myovant Sciences, Neurocrine Biosciences, Nippon Shinyaku, ObsEva SA, Organon, Pfizer, Sanofi, SWK, Tiumbio, Viramal, and others. 

Endometriosis Emerging and Marketed Drugs Covered in the Report Include:

• Linzagolix (OBE2109): ObsEva

• Relugolix (TAK-385): Myovant Sciences

• Eliapixant: Bayer

• Gefapixant (MK-7264): Merck

• MT-2990: Mitsubishi Tanabe Pharma Development America

• Orilissa: AbbVie

• Depo-subq Provera 104: Pfizer

• Lupron Depot: AbbVie

• Zoladex: AstraZeneca

• Synarel: Pfizer

• Danocrine: Sanofi

And Many Mor

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Endometriosis Current Treatment Patterns

4. Endometriosis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Endometriosis Late Stage Products (Phase-III)

7. Endometriosis Mid-Stage Products (Phase-II)

8. Endometriosis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Endometriosis Discontinued Products

13. Endometriosis Product Profiles

14. Key Companies in the Endometriosis Market

15. Key Products in the Endometriosis Therapeutics Segment

16. Dormant and Discontinued Products

17. Endometriosis Unmet Needs

18. Endometriosis Future Perspectives

19. Endometriosis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 

https://www.delveinsight.com/sample-request/endometriosis-pipeline-insight

Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/